Besides, in the stratified analyses of our study, we found that both mutational signature 6, cluster 3, and PTPRT mutation maintained their original prognostic capabilities in NSCLC/SKCM/BRCA patients, but failed to reach statistical significance in other primary tumor types with a smaller proportion (~30%). This evidence concerns the gene PTPRT and non-small cell lung carcinoma.